KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $1.7 billion.

  • AbbVie's Change in Accured Expenses rose 54794.01% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 41380.47%. This contributed to the annual value of $177.0 million for FY2024, which is 9539.06% down from last year.
  • As of Q3 2025, AbbVie's Change in Accured Expenses stood at $1.7 billion, which was up 54794.01% from $515.0 million recorded in Q2 2025.
  • AbbVie's Change in Accured Expenses' 5-year high stood at $2.5 billion during Q3 2023, with a 5-year trough of -$1.7 billion in Q2 2024.
  • Its 5-year average for Change in Accured Expenses is $476.5 million, with a median of $267.0 million in 2024.
  • Per our database at Business Quant, AbbVie's Change in Accured Expenses tumbled by 36388.89% in 2022 and then surged by 92842.11% in 2023.
  • AbbVie's Change in Accured Expenses (Quarter) stood at $265.0 million in 2021, then skyrocketed by 382.26% to $1.3 billion in 2022, then plummeted by 85.99% to $179.0 million in 2023, then skyrocketed by 596.65% to $1.2 billion in 2024, then skyrocketed by 38.73% to $1.7 billion in 2025.
  • Its Change in Accured Expenses stands at $1.7 billion for Q3 2025, versus $515.0 million for Q2 2025 and -$696.0 million for Q1 2025.